Trastuzumab rezetecan

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved: Adults with HER2-positive colorectal cancer after failure of oxaliplatin, fluorouracil... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Non-Small Cell Lung Cancer · Phase 3 · investigational in the USHER2-Positive Breast Cancer · Phase 3 · investigational in the USColorectal Cancer · Phase 3 · investigational in the USOvarian Cancer · Phase 3 · investigational in the USGastric Cancer · Phase 3 · investigational in the USBreast Cancer · Phase 3 · investigational in the US · under NMPA review

Also approved (3)
CN
  • Adults with HER2-positive colorectal cancer after failure of oxaliplatin, fluorouracil and irinotecanhengrui.com
  • Adults with locally advanced or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 therapieshkexnews.hk
  • Adults with unresectable locally advanced or metastatic NSCLC with activating HER2 (ERBB2) mutations who have received at least one prior systemic therapy (reported by NMPA 29 May 2025; one secondary source calls it conditional)1stoncology.com
Product first approved 2025

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (18)
Breast Cancer
NCT07679360 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-09-02 – 2032-12 · Triple Negative Breast Cancer
What this study did
NCT06126640 · Jiangsu HengRui Medicine Co., Ltd.
2023-11-20 – 2032-04 · HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
What this study did
NCT07669610 · Fudan University
2026-10-01 – 2029-03-30 · Breast Cancer, Triple Negative Breast Cancer (TNBC)
What this study did
NCT07760844 · Fudan University
2026-10-01 – 2029-03-30 · Breast Cancer, Triple Negative Breast Cancer (TNBC)
What this study did
NCT07111832 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-08-20 – 2028-12 · PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
What this study did
Colorectal Cancer
Gastric Cancer
HER2-Positive Breast Cancer
NCT07196774 · Jiangsu HengRui Medicine Co., Ltd.
2025-10-23 – 2028-12 · Early-stage or Locally Advanced HER2-positive Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07382687 · Fudan University
2026-02-26 – 2029-12-31 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07896005 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-12 – 2032-03 · Non Small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT06990503 · Tongji Hospital
2025-06-01 – 2035-06-01 · Ovarian Cancer
What this study did
Other / comorbidity
NCT07118527 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-08-18 – 2030-10 · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2 (84)
Breast Cancer
NCT07317778 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-02-15 – 2033-09-15 · Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer
What this study did
NCT07466303 · Xijing Hospital
2026-03-25 – 2031-04-01 · Breast Cancer, Serplulimab Combined With SHR-A1811 as Neoadjuvant Therapy for Triple-Negative Breast Cancer
What this study did
NCT06340230 · Shengjing Hospital
2024-08-23 – 2031-02-28 · HR Positive/HER2 Low Breast Cancer
What this study did
NCT07047755 · Henan Cancer Hospital
2025-07-01 – 2031-02-28 · Breast Cancer
What this study did
NCT07383818 · First Affiliated Hospital of Zhejiang University
2026-02-01 – 2031-02-01 · HR Positive/HER2 Low Breast Cancer
What this study did
NCT07340398 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-12-25 – 2031-01-01 · HER2-positive Early Breast Cancer
What this study did
NCT06927180 · Henan Cancer Hospital
2025-04-16 – 2030-12-01 · Breast Cancer Early Stage Breast Cancer (Stage 1-3)
What this study did
NCT05911958 · Henan Cancer Hospital
2023-07-05 – 2029-05-31 · HER2 Low Breast Carcinoma
What this study did
NCT07949695 · Tianjin Medical University Cancer Institute and Hospital
2026-11-01 – 2029-05-31 · HR Positive/HER2 Low Breast Cancer, Neoadjuvant Therapy, SHR-A1811, Toripalimab
What this study did
NCT07618923 · Tang-Du Hospital
2026-06 – 2029-01 · Breast Cancer, HR Positive/HER2 Low Breast Cancer
What this study did
NCT05749588 · Fudan University
2023-03-30 – 2028-12-31 · Triple-negative Breast Cancer
What this study did
NCT06975475 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-06-01 – 2028-06-01 · Breast Cancer
What this study did
NCT07305246 · First Hospital of China Medical University
2025-12 – 2027-09 · Breast Cancer
What this study did
NCT05076682 · Fudan University
2022-06-30 – 2027-03-31 · Triple-negative Breast Cancer
What this study did
NCT06592625 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2024-09-20 – 2026-02-28 · Untreated Early-stage or Locally Advanced Breast Cancer
What this study did
Colorectal Cancer
NCT07926477 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-12-01 – 2030-12-01 · Colorectal Cancer
What this study did
NCT06666166 · Yunpeng Liu
2024-12 – 2028-12 · Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Colorectal Cancer
What this study did
NCT07796763 · Jiangsu HengRui Medicine Co., Ltd.
2026-11-01 – 2028-11-01 · Advanced Colorectal Cancer Expressing HER2
What this study did
Gastric Cancer
NCT06881017 · China Medical University, China
2025-05-01 – 2029-11-01 · Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive
What this study did
NCT07102901 · Jiangsu HengRui Medicine Co., Ltd.
2025-09-05 – 2027-12 · Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05671822 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2023-03-14 – 2027-12 · HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07110571 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-08-28 – 2027-05 · Gastric Cancer, Gastroesophageal-junction Cancer
What this study did
HER2-Positive Breast Cancer
NCT07856303 · Fudan University
2026-10-01 – 2034-08 · HER2-positive Breast Cancer, Early Breast Cancer (EBC)
What this study did
NCT06973525 · Hebei Medical University Fourth Hospital
2025-09-01 – 2032-05-31 · HER2-positive Breast Cancer
What this study did
NCT07766772 · Fujian Cancer Hospital
2026-09-30 – 2031-12-31 · HER2 + Breast Cancer, Advanced Breast Cancer
What this study did
NCT07179939 · Fudan University
2025-09-10 – 2031-12-30 · HER2-positive Breast Cancer
What this study did
NCT07647263 · The First Affiliated Hospital of Soochow University
2026-03-24 – 2031-12 · HER2-positive Breast Cancer
What this study did
NCT07129187 · Chuan Wang
2025-10 – 2030-10 · Early Breast Cancer, HER2 + Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
What this study did
NCT07787338 · First Affiliated Hospital of Zhejiang University
2026-09 – 2030-10 · HER2-positive Breast Cancer
What this study did
NCT07416253 · Henan Cancer Hospital
2026-03 – 2030-07 · Breast Cancer
What this study did
NCT05635487 · Shengjing Hospital
2023-03-16 – 2030-02-28 · HER2-positive Breast Cancer
What this study did
NCT07417241 · Peking University Cancer Hospital & Institute
2026-03-31 – 2029-12-31 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07528898 · Hebei Medical University Fourth Hospital
2026-05 – 2029-07 · Breast Cancer
What this study did
NCT07132242 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-08-30 – 2028-12-31 · Metastatic Breast Cancer With HER2 Positive
What this study did
NCT06361979 · Huihua Xiong
2024-05 – 2026-05 · Breasr Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07935226 · Harbin Medical University
2026-12-15 – 2032-06-30 · Breast Cancer (Locally Advanced or Metastatic), HR Positive/HER2 Low Breast Cancer
What this study did
NCT07630103 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-06 – 2031-12 · Advanced Breast Cancer
What this study did
NCT07203729 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-03-01 – 2030-12-30 · HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis
What this study did
NCT07037199 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-08-18 – 2030-06-30 · Advanced Breast Cancer
What this study did
NCT07560475 · Tianjin Medical University Cancer Institute and Hospital
2026-06-10 – 2029-12-31 · HER2positive, Advanced Breast Cancer, HER2 + Breast Cancer
What this study did
NCT05769010 · Henan Cancer Hospital
2023-03-31 – 2029-06-30 · Metastatic Breast Cancer
What this study did
NCT07817082 · Tianjin Medical University Cancer Institute and Hospital
2026-09-01 – 2029-03-31 · Advanced Breast Cancer With Ultra-Low HER2 Expression
What this study did
NCT07466927 · Fudan University
2026-03-15 – 2029-01-15 · HER2-negative Breast Cancer
What this study did
NCT07497386 · Jiangsu HengRui Medicine Co., Ltd.
2026-04-28 – 2028-12 · Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer
What this study did
NCT07307287 · Tianjin Medical University Cancer Institute and Hospital
2025-12-20 – 2027-12-31 · SHR-A1811, HER2-Postive Breast Cancer, HR+ Breast Cancer, Early Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT06975462 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2025-06-01 – 2027-12-01 · Breast Cancer Metastatic
What this study did
NCT06433609 · Beijing GoBroad Hospital
2024-08-05 – 2027-11 · Advanced Breast Cancer
What this study did
NCT06649331 · Fudan University
2024-10-21 – 2027-09 · Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer, Breast Cancer
What this study did
NCT05594095 · Fudan University
2022-12-30 – 2026-12-01 · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
Phase 1/2 (15)
HER2-Positive Breast Cancer
NCT07177950 · Peking University Cancer Hospital & Institute
2025-09-30 – 2029-09-30 · Breast Cancer, Brain Metastases, Leptomeningeal Metastasis
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06788197 · Henan Cancer Hospital
2025-03 – 2029-03-31 · Breast Cancer, Locally Advanced or Metastatic Breast Cancer
What this study did
NCT06718933 · Fudan University
2025-01-08 – 2027-02-28 · Breast Cancer Metastatic, Breast Cancer Brain Metastases
What this study did
NCT06222879 · Shandong Suncadia Medicine Co., Ltd.
2024-02-20 – 2026-10-31 · Breast Cancer
What this study did
NCT05824325 · Fudan University
2023-03-14 – 2026-10-10 · Breast Cancer
What this study did
NCT05845138 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2023-07-25 – 2025-12-31 · Breast Cancer
What this study did
NCT05792410 · Jiangsu HengRui Medicine Co., Ltd.
2023-04 – 2025-02-27 · HER2 Low Advanced or Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05482568 · Jiangsu HengRui Medicine Co., Ltd.
2022-09-15 – 2026-12 · Advanced Non-small Cell Lung Cancer
What this study did
NCT04818333 · Jiangsu HengRui Medicine Co., Ltd.
2021-04-23 – 2025-06 · Advanced Non-small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT06990516 · Tongji Hospital
2025-06-01 – 2035-06-01 · Ovarian Cancer
What this study did
NCT06840002 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-03-18 – 2026-12 · Ovarian Cancer
What this study did
Other / comorbidity
NCT07140393 · Jiangsu HengRui Medicine Co., Ltd.
2025-10-28 – 2028-10 · Solid Tumor
What this study did
NCT07231211 · Shanghai Shengdi Pharmaceutical Co., Ltd
2025-11-20 – 2027-12 · Solid Tumors
What this study did
NCT06859775 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-04-25 – 2027-01 · Recurrent or Metastatic Cervical Cancer
What this study did
NCT06015048 · Jiangsu HengRui Medicine Co., Ltd.
2023-08-11 – 2026-12-29 · HER2-expressing Advanced Solid Tumors
What this study did
Phase 1 (4)
Colorectal Cancer
NCT04513223 · Jiangsu HengRui Medicine Co., Ltd.
2021-03-30 – 2025-03-28 · Gastric Cancer, Colorectal Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06710990 · Jiangsu HengRui Medicine Co., Ltd.
2025-02-17 – 2025-10-15 · Advanced Breast Cancer
What this study did
Other / comorbidity
NCT07275242 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-12-23 – 2027-12 · Solid Tumor
What this study did
NCT04446260 · Jiangsu HengRui Medicine Co., Ltd.
2020-09-07 – 2025-06-04 · Advanced Solid Tumors
What this study did
Phase 4 (2)
HER2-Positive Breast Cancer
NCT07589699 · The First Affiliated Hospital with Nanjing Medical University
2026-05-31 – 2031-12-31 · Breast Cancer, HER2-positive Breast Cancer, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07600164 · Peking University People's Hospital
2026-07-06 – 2031-12-30 · HER2 + Breast Cancer, Advanced Breast Cancer
What this study did
Early phase / not applicable (1)
Non-Small Cell Lung Cancer
NCT07377916 · The First Affiliated Hospital of Guangzhou Medical University
2026-02-15 – 2029-12-31 · Non-Small Cell Lung Cancer
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT07892274 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-11-01 – 2031-12-31 · Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (1)
Breast Cancer
NCT07100600 · Henan Cancer Hospital
2025-08-30 – 2032-12-30 · HER2-positive Advanced Breast Cancer, Brain Metastases, Radiotherapy
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, 4 of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Trastuzumab Rezetecan: this drugPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
APG-2449Phase 3Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRPartial signal
NCT06380348: Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24).
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-APartial signal
NCT03952403: ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC.
IBI305Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT02954172: Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33.
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890
Phase 3(overall)
Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT03533127: LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated.
NiraparibPhase 3Small moleculePARP1/2Partial signal
NCT04475939: Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population (Up to 52 months): Niraparib + Pembrolizumab 5.55 Months (95% CI 4.14 to 8.28) vs Placebo + Pembrolizumab 5.55 Months (95% CI 4.21 to 7.16) missed
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signal
NCT05865990: LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001)
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
PyrotinibPhase 3Small moleculeEGFR/HER1, HER2, HER4Partial signalNo reviewed efficacy summary in this indication
Retlirafusp AlfaPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signalNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesPartial signal
NCT03693547: Primary endpoint ORR 15.4% (95% CI 4.4%-34.9%) in ITT (N = 26); 19.0% (95% CI 5.4%-41.9%) in per-protocol (N = 21)
Docetaxel (HB1801)Phase 2/3Small moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 2Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 2Small moleculeHDACWeak signal
NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed
Denosumab (Xgeva)Phase 2Monoclonal antibodyRANKLPartial signalFeatured results are non-efficacy only in this race
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
HRS-4508Phase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
NeratinibPhase 2Small moleculeEGFR/HER2Partial signal
NCT00266877: Objective response rate (primary endpoint): 3% in arm A (prior TKI, EGFR-mutation positive, n=91), 0% in arm B (prior TKI, EGFR wild-type, n=48), 0% in arm C (TKI-naive, n=28); 3 of 4 patients with exon 18 G719X EGFR mutation had a partial response missed
Olvimulogene NanivacirepvecPhase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
PrifetrastatPhase 2Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 2Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 2Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
TUB-040Phase 2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
ASP546CPhase 1/2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 1/2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 1/2PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
177Lu-DWJ155Phase 1RadiopharmaceuticalHER2not yet gradedNo reviewed efficacy summary in this indication
AfivastobartPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BL-M17D1Phase 1Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 1Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
KJ015Phase 1Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T CellPhase 1Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
MT-304
Phase 1(overall)
RNA / oligonucleotideHER2not yet gradedNo reviewed efficacy summary in this indication
NVL-330Phase 1Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
ONO-4578Phase 1Small moleculeProstaglandin E2 receptor 4 (EP4)not yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
RAD202
Phase 1(overall)
RadiopharmaceuticalHER2
not yet graded(overall)
No reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
GSK6855547
—(overall)
Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 126 furthest-along competitors are listed; 485 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(94 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trastuzumab rezetecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
November 2026 (1)
Phase 1/2HER2-expressing Advanced Solid TumorsRecruiting
Est. primary completion 2026-11 · NCT06015048 · CT.gov ↗
What to watch
December 2026 (6)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2026-12 · NCT06840002 · CT.gov ↗
What to watch
Phase 2Advanced Salivary Gland CarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT05924256 · CT.gov ↗
What to watch
Phase 2HER2 Expression / Amplification in Patients With Biliary Tract CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT06413745 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT05076682 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05424835 · CT.gov ↗
What to watch
2027 (27)
March 2027 (4)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-03 · NCT07305246 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-03 · NCT06547736 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-03 · NCT07416253 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-03 · NCT06433609 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2Biliary Tract Neoplasms ImmunotherapyRecruiting
Est. primary completion 2027-04-15 · NCT07704177 · CT.gov ↗
What to watch
Phase 2Biliary Tract Neoplasms ImmunotherapyRecruiting
Est. primary completion 2027-04-29 · NCT07670273 · CT.gov ↗
What to watch
May 2027 (2)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2027-05 · NCT06828354 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-05-31 · NCT06973525 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1Solid TumorRecruiting
Est. primary completion 2027-06 · NCT07275242 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06975475 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06975462 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2027-06-30 · NCT06123494 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-07 · NCT07528898 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-07-01 · NCT07630077 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-08-30 · NCT07778745 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Urachal Cancer, Advanced Solid Tumor Cancer, Antibody-drug ConjugatesRecruiting
Est. primary completion 2027-09-11 · NCT07309770 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-10 · NCT07140393 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Biliary Tract Cancer (BTC), First-line TherapyNot yet recruiting
Est. primary completion 2027-11 · NCT07129018 · CT.gov ↗
What to watch
December 2027 (9)
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-12 · NCT07102901 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07281209 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-12 · NCT05671822 · CT.gov ↗
What to watch
Phase 3HER2-Positive Breast CancerActive not recruiting
Est. primary completion 2027-12 · NCT07196774 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07307287 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07489703 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2GC, GEJCNot yet recruiting
Est. primary completion 2027-12-31 · NCT07817654 · CT.gov ↗
What to watch
2028 (34)
January 2028 (2)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-15 · NCT07466927 · CT.gov ↗
What to watch
Phase 2mCRC, HER2, Targeted Therapy, Antibody-drug ConjugatesNot yet recruiting
Est. primary completion 2028-01-30 · NCT07355764 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-02-01 · NCT07383818 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-02-01 · NCT07466303 · CT.gov ↗
What to watch
March 2028 (3)
Phase 3Breast CancerRecruiting
Est. primary completion 2028-03 · NCT07111832 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-03-30 · NCT07776171 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-03-31 · NCT06788197 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-05-01 · NCT07796763 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-05-31 · NCT07949695 · CT.gov ↗
What to watch
June 2028 (7)
Phase 2HER2-positive Locally Advanced or Metastatic Biliary Tract CancerRecruiting
Est. primary completion 2028-06 · NCT06778031 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06 · NCT07497386 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07618923 · CT.gov ↗
What to watch
Phase 2Chemotherapy-Induced Nausea and Vomiting (CINV)Recruiting
Est. primary completion 2028-06-01 · NCT07726433 · CT.gov ↗
What to watch
Phase 2Muscle-Invasive Bladder Cancer (MIBC)Active not recruiting
Est. primary completion 2028-06-01 · NCT07624201 · CT.gov ↗
What to watch
Phase 2Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder CancerNot yet recruiting
Est. primary completion 2028-06-05 · NCT07639983 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT07037199 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-07 · NCT06666166 · CT.gov ↗
What to watch
Phase 2Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma RecurrentRecruiting
Est. primary completion 2028-07-01 · NCT07241793 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2UTUCRecruiting
Est. primary completion 2028-08-15 · NCT07741448 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-08-30 · NCT07132242 · CT.gov ↗
What to watch
September 2028 (5)
Phase 1/2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07177950 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-09-30 · NCT07817082 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07843303 · CT.gov ↗
What to watch
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07669610 · CT.gov ↗
What to watch
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2028-09-30 · NCT07760844 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-10-15 · NCT07317778 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) AdenocarcinomaNot yet recruiting
Est. primary completion 2028-10-31 · NCT07912957 · CT.gov ↗
What to watch
December 2028 (7)
Phase 2Muscle-Invasive Bladder Cancer (MIBC)Not yet recruiting
Est. primary completion 2028-12 · NCT07865611 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT05769010 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07631884 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07560475 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07382687 · CT.gov ↗
What to watch
Phase 4HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT07589699 · CT.gov ↗
What to watch
2029 (12)
January 2029 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2029-01-31 · NCT07417241 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-03 · NCT07699952 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2029-04 · NCT07787338 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2029-04-30 · NCT07802288 · CT.gov ↗
What to watch
May 2029 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2029-05-01 · NCT06927180 · CT.gov ↗
What to watch
June 2029 (2)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2029-06 · NCT07647263 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-06-30 · NCT07377916 · CT.gov ↗
What to watch
August 2029 (2)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2029-08-01 · NCT06881017 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-08-30 · NCT07781202 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Colorectal CancerRecruiting
Est. primary completion 2029-09 · NCT07676162 · CT.gov ↗
What to watch
December 2029 (2)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07836543 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2029-12-01 · NCT07926477 · CT.gov ↗
What to watch
2030 (8)
April 2030 (1)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2030-04 · NCT06126640 · CT.gov ↗
What to watch
June 2030 (4)
Phase 2Leptomeningeal Metastases, Solid TumorsNot yet recruiting
Est. primary completion 2030-06 · NCT07833657 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT06990516 · CT.gov ↗
What to watch
Phase 3Ovarian CancerNot yet recruiting
Est. primary completion 2030-06-01 · NCT06990503 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-06-15 · NCT07203729 · CT.gov ↗
What to watch
October 2030 (1)
Phase 3Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2030-10 · NCT07118527 · CT.gov ↗
What to watch
December 2030 (2)
Phase 3Breast CancerRecruiting
Est. primary completion 2030-12 · NCT07679360 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2030-12-30 · NCT07179939 · CT.gov ↗
What to watch
2031 (5)
February 2031 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-02 · NCT07896005 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-06 · NCT07630103 · CT.gov ↗
What to watch
December 2031 (3)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2031-12-15 · NCT07935226 · CT.gov ↗
What to watch
Phase 4HER2-Positive Breast CancerRecruiting
Est. primary completion 2031-12-30 · NCT07600164 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2031-12-31 · NCT07766772 · CT.gov ↗
What to watch
2032 (1)
August 2032 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2032-08 · NCT07856303 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

2 July 2026Filing acceptedNMPA accepts the marketing application for trastuzumab rezetecan in HER2-low breast cancer (CXSS2600103), with priority review
China, NMPA · Jiangsu Hengrui Pharmaceuticals · Source ↗